Baidu
map

J Rheumatol:疼痛和自我报告关节肿胀是类风湿性关节炎患者报告发作的主要驱动因素

2019-12-15 xiangting MedSci原创

在RA患者中,自我报告的急性发作很常见,主要使用镇痛药治疗,并由疾病活动性指标较高证实,与疼痛和患者报告的关节肿胀独立相关,并与治疗升级有关。

这项研究旨在前瞻性分析类风湿性关节炎患者(RA)自我报告的发作特征及其与疾病活动性和患者报告结局(PROs)的纵向关联。

纳入DAS28CRP<3.2,并且在基线、第6和12个月无关节肿胀的连续性RA患者。评估包括关节计数、DAS28-CRP、视觉模拟量表整体评估(EGA)和PROs。患者每3个月完成一次FLARERA和RA发作问卷(RA-FQ),并公布自我管理策略。比较了急性发作与非急性发作患者,以及自我报告急性发作状态(是/否)与疾病活动性、PROs和治疗升级之间的纵向关联。

80名RA患者中(74%为女性,平均年龄(SD)63岁(10),病程11年(7),基线DAS28-CRP 1.9(0.6)),64名患者(80%)报告在12个月内至少发生过1次急性发作。55%的急性发作持续不到一周。常见的自我管理策略是止痛药(50%)和限制活动(38%)。与无急性发作患者相比,报告处于发作状态的患者疾病活动性指标和PROs更高。在部分调整模型中,所有的发作域、患者报告的肿胀和触痛关节计数以及疾病活动性指标均与急性发作相关。在完全调整分析中,当前的急性发作与疼痛(OR 1.85,[95%CI 1.30; 2.60])、患者报告的关节肿胀(OR 1.18 [1.03; 1.36])和EGA较高独立相关(OR 1.15 [1.04; 1.28])。

在RA患者中,自我报告的急性发作很常见,主要使用镇痛药治疗,并由疾病活动性指标较高证实,与疼痛和患者报告的关节肿胀独立相关,并与治疗升级有关。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1763903, encodeId=cef81e63903db, content=<a href='/topic/show?id=8dce86164b8' target=_blank style='color:#2F92EE;'>#自我报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86164, encryptionId=8dce86164b8, topicName=自我报告)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f8137597854, createdName=12498aa2m74(暂无昵称), createdTime=Tue Jun 30 04:45:00 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028387, encodeId=53b5202838ebf, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Nov 19 00:45:00 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266069, encodeId=372e126606986, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Dec 17 02:45:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334183, encodeId=cdf8133418331, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Tue Dec 17 02:45:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483634, encodeId=3b7414836342c, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Tue Dec 17 02:45:00 CST 2019, time=2019-12-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1763903, encodeId=cef81e63903db, content=<a href='/topic/show?id=8dce86164b8' target=_blank style='color:#2F92EE;'>#自我报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86164, encryptionId=8dce86164b8, topicName=自我报告)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f8137597854, createdName=12498aa2m74(暂无昵称), createdTime=Tue Jun 30 04:45:00 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028387, encodeId=53b5202838ebf, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Nov 19 00:45:00 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266069, encodeId=372e126606986, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Dec 17 02:45:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334183, encodeId=cdf8133418331, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Tue Dec 17 02:45:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483634, encodeId=3b7414836342c, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Tue Dec 17 02:45:00 CST 2019, time=2019-12-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1763903, encodeId=cef81e63903db, content=<a href='/topic/show?id=8dce86164b8' target=_blank style='color:#2F92EE;'>#自我报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86164, encryptionId=8dce86164b8, topicName=自我报告)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f8137597854, createdName=12498aa2m74(暂无昵称), createdTime=Tue Jun 30 04:45:00 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028387, encodeId=53b5202838ebf, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Nov 19 00:45:00 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266069, encodeId=372e126606986, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Dec 17 02:45:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334183, encodeId=cdf8133418331, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Tue Dec 17 02:45:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483634, encodeId=3b7414836342c, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Tue Dec 17 02:45:00 CST 2019, time=2019-12-17, status=1, ipAttribution=)]
    2019-12-17 lmm397
  4. [GetPortalCommentsPageByObjectIdResponse(id=1763903, encodeId=cef81e63903db, content=<a href='/topic/show?id=8dce86164b8' target=_blank style='color:#2F92EE;'>#自我报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86164, encryptionId=8dce86164b8, topicName=自我报告)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f8137597854, createdName=12498aa2m74(暂无昵称), createdTime=Tue Jun 30 04:45:00 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028387, encodeId=53b5202838ebf, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Nov 19 00:45:00 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266069, encodeId=372e126606986, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Dec 17 02:45:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334183, encodeId=cdf8133418331, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Tue Dec 17 02:45:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483634, encodeId=3b7414836342c, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Tue Dec 17 02:45:00 CST 2019, time=2019-12-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1763903, encodeId=cef81e63903db, content=<a href='/topic/show?id=8dce86164b8' target=_blank style='color:#2F92EE;'>#自我报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86164, encryptionId=8dce86164b8, topicName=自我报告)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f8137597854, createdName=12498aa2m74(暂无昵称), createdTime=Tue Jun 30 04:45:00 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028387, encodeId=53b5202838ebf, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Nov 19 00:45:00 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266069, encodeId=372e126606986, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Dec 17 02:45:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334183, encodeId=cdf8133418331, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Tue Dec 17 02:45:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483634, encodeId=3b7414836342c, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Tue Dec 17 02:45:00 CST 2019, time=2019-12-17, status=1, ipAttribution=)]

相关资讯

吉利德的JAK1抑制剂filgotinib治疗类风湿性关节炎III期临床成功

吉利德(Gilead)宣布,其JAK1抑制剂filgotinib在一项评估其治疗中度至重度活跃性类风湿性关节炎(RA)的疗效和安全性的III期试验中被证明是成功的。

Arthritis Rheumatol:类风湿性关节炎的B细胞滑膜炎和临床表型

这项研究描述了一种有效的半定量组织学B细胞评分,该评分可通过数字或分子分析重复B细胞定量。研究证明在大量既定RA患者中,正发生B细胞丰富型滑膜炎,而这并没有被标准的临床评估所发现。

J Rheumatol:颈椎受累在使用目标治疗策略的类风湿性关节炎患者中很罕见

早期、缓解靶向的强化治疗降低了CSI的发病率,这项研究结果表明,强化治疗从长远来看也能阻止颈椎受累的发展。

欧洲委员会批准Celltrion的英夫利昔单抗皮下制剂仿制药Remsima SC,用于治疗类风湿性关节炎

Celltrion公布其TNF-α单抗,英夫利昔单抗皮下(SC)生物仿制药Remsima SC治疗慢性病,溃疡性结肠炎和类风湿性关节炎(RA)患者中的阳性数据。除阳性数据外,该药物已获得欧洲委员会对类风湿性关节炎患者的批准,标志着该药物成为世界上首个获批的英夫利昔单抗皮下制剂。

J Rheumatol:类风湿性关节炎患者的矫形外科手术

尽管总的OS率没有变化,但所有年龄段的关节融合术发生率均有所下降。

J Rheumatol:定义类风湿性关节炎抗TNF治疗的原发性和继发性无应答

医师报告的1ry无应答与未达到DAS28-ESR LDA或CDAI LDA的相关性更高,而2ry无应答与实际停药时间相关。

Baidu
map
Baidu
map
Baidu
map